Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 201–300 of 1,021
End-joining, translocations and cancer
Bunting, S. F., & Nussenzweig, A. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3537 · Cited by 359
The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line
Adey, A., Burton, J. N., Kitzman, J. O., Hiatt, J. B., Lewis, A. P., Martin, B. K., Qiu, R., Lee, C., & Shendure, J. (2013) · Nature · doi:10.1038/nature12064 · Cited by 362
Molecular biology of lung cancer.
Cooper, W. A., Lam, D. C.-L., O'Toole, S. A., & Minna, J. D. (2013) · PubMed · doi:10.3978/j.issn.2072-1439.2013.08.03 · Cited by 303
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
Iglesia, M. D., Parker, J. S., Hoadley, K. A., Serody, J. S., Perou, C. M., & Vincent, B. G. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw144 · Cited by 360
NOTCH1 Mutations Occur Early during Cutaneous Squamous Cell Carcinogenesis
South, A. P., Purdie, K. J., Watt, S. A., Haldenby, S., den Breems, N. Y., Dimon, M., Arron, S. T., Kluk, M. J., Aster, J. C., McHugh, A., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.154 · Cited by 357
Pan-Cancer Landscape of Aberrant DNA Methylation across Human Tumors
Saghafinia, S., Mina, M., Riggi, N., Hanahan, D., & Ciriello, G. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.09.082 · Cited by 357
Driver and Passenger Mutations in Cancer
Pon, J. R., & Marra, M. A. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 355
The AMP-activated protein kinase (AMPK) and cancer: Many faces of a metabolic regulator
Faubert, B., Vincent, E. E., Poffenberger, M. C., & Jones, R. G. (2015) · Cancer Letters · doi:10.1016/j.canlet.2014.01.018 · Cited by 354
DNA polymerase ɛ and δ exonuclease domain mutations in endometrial cancer
Church, D. N., Briggs, S. E. W., Palles, C., Domingo, E., Kearsey, S. J., Grimes, J. M., Gorman, M., Martin, L., Howarth, K. M., Hodgson, S. V., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt131 · Cited by 352
Li, B., Cui, Y., Diehn, M., & Li, R. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.1609 · Cited by 514
Targeting p53 for the treatment of cancer
Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.005 · Cited by 349
Identification of focally amplified lineage-specific super-enhancers in human epithelial cancers
Zhang, X., Choi, P. S., Francis, J. M., Imielinski, M., Watanabe, H., Cherniack, A. D., & Meyerson, M. (2016) · Nature Genetics · doi:10.1038/ng.3470 · Cited by 348
Pearce, O. M. T., Delaine-Smith, R. M., Maniati, E., Nichols, S., Wang, J., Böhm, S., Rajeeve, V., Ullah, D., Chakravarty, P., Jones, R. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0284 · Cited by 349
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0127 · Cited by 345
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Campbell, J. D., Yau, C., Bowlby, R., Liu, Y., Brennan, K., Fan, H., Taylor, A. M., Wang, C., Walter, V., Akbani, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.063 · Cited by 342
Yan, J., Risacher, S. L., Shen, L., & Saykin, A. J. (2017) · Briefings in Bioinformatics · doi:10.1093/bib/bbx066 · Cited by 325
Functional Enhancers Shape Extrachromosomal Oncogene Amplifications
Morton, A. R., Dogan-Artun, N., Faber, Z. J., MacLeod, G., Bartels, C. F., Piazza, M. S., Allan, K. C., Mack, S. C., Wang, X., Gimple, R. C., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.039 · Cited by 343
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Garraway, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8934 · Cited by 340
Giving AXL the axe: targeting AXL in human malignancy
Gay, C. M., Balaji, K., & Byers, L. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2016.428 · Cited by 334
Deep Convolutional Neural Networks Enable Discrimination of Heterogeneous Digital Pathology Images
Khosravi, P., Kazemi, E., Imielinski, M., Elemento, O., & Hajirasouliha, I. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2017.12.026 · Cited by 334
Self-citationIntron retention is a widespread mechanism of tumor-suppressor inactivation
Jung, H., Lee, D., Lee, J., Park, D., Kim, Y. J., Park, W.-Y., Hong, D., Park, P. J., & Lee, E. (2015) · Nature Genetics · doi:10.1038/ng.3414 · Cited by 339
Cancer overdiagnosis: a biological challenge and clinical dilemma
Srivastava, S., Koay, E. J., Borowsky, A. D., De Marzo, A. M., Ghosh, S., Wagner, P. D., & Kramer, B. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0142-8 · Cited by 337
Increased global transcription activity as a mechanism of replication stress in cancer
Kotsantis, P., Silva, L. M., Irmscher, S., Jones, R. M., Folkes, L., Gromak, N., & Petermann, E. (2016) · Nature Communications · doi:10.1038/ncomms13087 · Cited by 336
Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes
Yang, L., Luquette, L. J., Gehlenborg, N., Xi, R., Haseley, P. S., Hsieh, C.-H., Zhang, C., Ren, X., Protopopov, A., Chin, L., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.010 · Cited by 337
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
ZEB1 drives epithelial-to-mesenchymal transition in lung cancer
Larsen, J. E., Nathan, V., Osborne, J. K., Farrow, R. K., Deb, D., Sullivan, J. P., Dospoy, P. D., Augustyn, A., Hight, S. K., Sato, M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci76725 · Cited by 334
Transcription factor NRF2 regulates miR-1 and miR-206 to drive tumorigenesis
Singh, A., Happel, C., Manna, S. K., Acquaah-Mensah, G., Carrerero, J., Kumar, S., Nasipuri, P., Krausz, K. W., Wakabayashi, N., Dewi, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66353 · Cited by 333
“Gain of NRF2 function by means of various mechanisms has been reported in lung, breast, skin, esophageal, gallbladder, renal, pancreatic, and endometrial cancer (5–13).”
Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population
Sawada, G., Niida, A., Uchi, R., Hirata, H., Shimamura, T., Suzuki, Y., Shiraishi, Y., Chiba, K., Imoto, S., Takahashi, Y., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.035 · Cited by 332
The impact of site-specific digital histology signatures on deep learning model accuracy and bias
Howard, F. M., Dolezal, J., Kochanny, S., Schulte, J., Chen, H., Heij, L., Huo, D., Nanda, R., Olopade, O. I., Kather, J. N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24698-1 · Cited by 330
Walter, V., Yin, X., Wilkerson, M. D., Cabanski, C. R., Zhao, N., Du, Y., Ang, M. K., Hayward, M. C., Salazar, A. H., Hoadley, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056823 · Cited by 327
Zhao, W., He, X., Hoadley, K. A., Parker, J. S., Hayes, D. N., & Perou, C. M. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-419 · Cited by 320
Refining the treatment of NSCLC according to histological and molecular subtypes
Thomas, A., Liu, S. V., Subramaniam, D. S., & Giaccone, G. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.90 · Cited by 321
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 319
Identification of differentially methylated cell types in epigenome-wide association studies
Zheng, S. C., Breeze, C. E., Beck, S., & Teschendorff, A. E. (2018) · Nature Methods · doi:10.1038/s41592-018-0213-x · Cited by 320
Gallbladder carcinoma: Prognostic factors and therapeutic options
Goetze, T. O. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i43.12211 · Cited by 319
The evolution of lung cancer and impact of subclonal selection in TRACERx
Frankell, A. M., Dietzen, M., Al Bakir, M., Lim, E. L., Karasaki, T., Ward, S., Veeriah, S., Colliver, E., Huebner, A., Bunkum, A., et al. (2023) · Nature · doi:10.1038/s41586-023-05783-5 · Cited by 313
NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression
Chen, D., Tavana, O., Chu, B., Erber, L., Chen, Y., Baer, R., & Gu, W. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.009 · Cited by 317
SWI/SNF Chromatin Remodeling and Human Malignancies
Masliah-Planchon, J., Bièche, I., Guinebretière, J.-M., Bourdeaut, F., & Delattre, O. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040445 · Cited by 316
Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Shi, R., Radulovich, N., Ng, C., Liu, N., Notsuda, H., Cabanero, M., Martins-Filho, S. N., Raghavan, V., Li, Q., Mer, A. S., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1376 · Cited by 316
A radiogenomic dataset of non-small cell lung cancer
Bakr, S., Gevaert, O., Echegaray, S., Ayers, K., Zhou, M., Shafiq, M., Zheng, H., Benson, J. A., Zhang, W., Leung, A. N. C., et al. (2018) · Scientific Data · doi:10.1038/sdata.2018.202 · Cited by 311
Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids
Fernandez-Cuesta, L., Peifer, M., Lu, X., Sun, R., Ozretić, L., Seidel, D., Zander, T., Leenders, F., George, J., Müller, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4518 · Cited by 317
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 311
TCGA Workflow: Analyze cancer genomics and epigenomics data using Bioconductor packages
Silva, T. C., Colaprico, A., Olsen, C., D'Angelo, F., Bontempi, G., Ceccarelli, M., & Noushmehr, H. (2016) · F1000Research · doi:10.12688/f1000research.8923.1 · Cited by 306
Ridge, C., McErlean, A., & Ginsberg, M. (2013) · Seminars in Interventional Radiology · doi:10.1055/s-0033-1342949 · Cited by 295
–Omic and Electronic Health Record Big Data Analytics for Precision Medicine
Wu, P.-Y., Cheng, C.-W., Kaddi, C. D., Venugopalan, J., Hoffman, R., & Wang, M. D. (2017) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2573285 · Cited by 303
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 303
The genomic landscape of juvenile myelomonocytic leukemia
Stieglitz, E., Taylor-Weiner, A. N., Chang, T. Y., Gelston, L. C., Wang, Y.-D., Mazor, T., Esquivel, E., Yu, A., Seepo, S., Olsen, S. R., et al. (2015) · Nature Genetics · doi:10.1038/ng.3400 · Cited by 301
DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer
Bashashati, A., Haffari, G., Ding, J., Ha, G., Lui, K., Rosner, J., Huntsman, D. G., Caldas, C., Aparicio, S. A., & Shah, S. P. (2012) · Genome Biology · doi:10.1186/gb-2012-13-12-r124 · Cited by 302
Kerr, K. M., Bubendorf, L., Edelman, M. J., Marchetti, A., Mok, T., Novello, S., O'Byrne, K., Stahel, R., Peters, S., Felip, E., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu145 · Cited by 298
Deep learning-based prediction of the T cell receptor–antigen binding specificity
Lu, T., Zhang, Z., Zhu, J., Wang, Y., Jiang, P., Xiao, X., Bernatchez, C., Heymach, J. V., Gibbons, D. L., Wang, J., et al. (2021) · Nature Machine Intelligence · doi:10.1038/s42256-021-00383-2 · Cited by 295
Battling Chemoresistance in Cancer: Root Causes and Strategies to Uproot Them
Ramos, A., Sadeghi, S., & Tabatabaeian, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179451 · Cited by 289
The Molecular Balancing Act of p16INK4a in Cancer and Aging
LaPak, K. M., & Burd, C. E. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 291
Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma
Chen, X., Stewart, E., Shelat, A. A., Qu, C., Bahrami, A., Hatley, M., Wu, G., Bradley, C., McEvoy, J., Pappo, A., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.002 · Cited by 294
Genomic Analysis of Metastatic Cutaneous Squamous Cell Carcinoma
Li, Y. Y., Hanna, G. J., Laga, A. C., Haddad, R. I., Lorch, J. H., & Hammerman, P. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1773 · Cited by 285
Scientific Advances in Lung Cancer 2015
Tsao, A. S., Scagliotti, G. V., Bunn, P. A., Carbone, D. P., Warren, G. W., Bai, C., de Koning, H. J., Yousaf-Khan, A. U., McWilliams, A., Tsao, M. S., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.03.012 · Cited by 284
Paul, M. K., Bisht, B., Darmawan, D. O., Chiou, R., Ha, V. L., Wallace, W. D., Chon, A. T., Hegab, A. E., Grogan, T., Elashoff, D. A., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.05.009 · Cited by 286
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
TRACERx Consortium, AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., Lund, T., Moore, D. A., Salgado, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0900-x · Cited by 286
The Circular RNA circPRKCI Promotes Tumor Growth in Lung Adenocarcinoma
Qiu, M., Xia, W., Chen, R., Wang, S., Xu, Y., Ma, Z., Xu, W., Zhang, E., Wang, J., Fang, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2808 · Cited by 285
Ganly, I., Makarov, V., Deraje, S., Dong, Y., Reznik, E., Seshan, V., Nanjangud, G., Eng, S., Bose, P., Kuo, F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.002 · Cited by 283
Lung cancer epigenetics: From knowledge to applications
Duruisseaux, M., & Esteller, M. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.005 · Cited by 283
Signaling through cyclin D-dependent kinases
Choi, Y. J., & Anders, L. (2014) · Oncogene · doi:10.1038/onc.2013.137 · Cited by 278
Lee, G., Lee, H. Y., Park, H., Schiebler, M. L., van Beek, E. J. R., Ohno, Y., Seo, J. B., & Leung, A. (2017) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.09.005 · Cited by 282
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data
Mo, Q., Shen, R., Guo, C., Vannucci, M., Chan, K. S., & Hilsenbeck, S. G. (2018) · Biostatistics · doi:10.1093/biostatistics/kxx017 · Cited by 280
Assessing the clinical utility of cancer genomic and proteomic data across tumor types
Yuan, Y., Van Allen, E. M., Omberg, L., Wagle, N., Amin-Mansour, A., Sokolov, A., Byers, L. A., Xu, Y., Hess, K. R., Diao, L., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2940 · Cited by 280
A Prognostic DNA Methylation Signature for Stage I Non–Small-Cell Lung Cancer
Sandoval, J., Mendez-Gonzalez, J., Nadal, E., Chen, G., Carmona, F. J., Sayols, S., Moran, S., Heyn, H., Vizoso, M., Gomez, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.5516 · Cited by 278
Germline BAP1 Mutations Predispose to Renal Cell Carcinomas
Popova, T., Hebert, L., Jacquemin, V., Gad, S., Caux-Moncoutier, V., Dubois-d’Enghien, C., Richaudeau, B., Renaudin, X., Sellers, J., Nicolas, A., et al. (2013) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2013.04.012 · Cited by 279
Iglesia, M. D., Vincent, B. G., Parker, J. S., Hoadley, K. A., Carey, L. A., Perou, C. M., & Serody, J. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3368 · Cited by 277
Early Detection of Lung Cancer Using DNA Promoter Hypermethylation in Plasma and Sputum
Hulbert, A., Jusue-Torres, I., Stark, A., Chen, C., Rodgers, K., Lee, B., Griffin, C., Yang, A., Huang, P., Wrangle, J., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1371 · Cited by 275
Clinical Implications of Genomic Discoveries in Lung Cancer
Swanton, C., & Govindan, R. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1504688 · Cited by 269
Yoo, S.-K., Song, Y. S., Lee, E. K., Hwang, J., Kim, H. H., Jung, G., Kim, Y. A., Kim, S.-J., Cho, S. W., Won, J.-K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10680-5 · Cited by 268
Sebestyén, E., Singh, B., Miñana, B., Pagès, A., Mateo, F., Pujana, M. A., Valcárcel, J., & Eyras, E. (2016) · Genome Research · doi:10.1101/gr.199935.115 · Cited by 276
Role of Nrf2 and Its Activators in Respiratory Diseases
Liu, Q., Gao, Y., & Ci, X. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7090534 · Cited by 267
Dai, J., Lv, J., Zhu, M., Wang, Y., Qin, N., Ma, H., He, Y.-Q., Zhang, R., Tan, W., Fan, J., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30144-4 · Cited by 265
Deciphering the cells of origin of squamous cell carcinomas
Sánchez-Danés, A., & Blanpain, C. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0024-5 · Cited by 261
The emerging roles of ARID1A in tumor suppression
Wu, R.-C., Wang, T.-L., & Shih, I.-M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.28411 · Cited by 261
The cancer genome atlas pan-cancer analysis project
Mills, G. B., Mills Shaw, K. R., Shmulevich, I., Stuart, J. M., Ellrott, K., Sander, C., The Cancer Genome Atlas Research Network, Collisson, E. A., Ozenberger, B. A., & Weinstein, J. N. (2019) · PubMed · doi:10.17615/670y-yr53 · Cited by 261
Teixeira, V. H., Pipinikas, C. P., Pennycuick, A., Lee-Six, H., Chandrasekharan, D., Beane, J., Morris, T. J., Karpathakis, A., Feber, A., Breeze, C. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0323-0 · Cited by 259
Hast, B. E., Goldfarb, D., Mulvaney, K. M., Hast, M. A., Siesser, P. F., Yan, F., Hayes, D. N., & Major, M. B. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4400 · Cited by 259
Smoking, p53 Mutation, and Lung Cancer
Gibbons, D. L., Byers, L. A., & Kurie, J. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0539 · Cited by 255
Lin, D.-C., Wang, M.-R., & Koeffler, H. P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.06.066 · Cited by 251
Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors
Goh, G., Scholl, U. I., Healy, J. M., Choi, M., Prasad, M. L., Nelson-Williams, C., Kunstman, J. W., Korah, R., Suttorp, A.-C., Dietrich, D., et al. (2014) · Nature Genetics · doi:10.1038/ng.2956 · Cited by 251
Poirier, J. T., Gardner, E. E., Connis, N., Moreira, A. L., de Stanchina, E., Hann, C. L., & Rudin, C. M. (2015) · Oncogene · doi:10.1038/onc.2015.38 · Cited by 248
Cause and Consequence of Cancer/Testis Antigen Activation in Cancer
Whitehurst, A. W. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140326 · Cited by 250
A Pan-cancer Transcriptome Analysis Reveals Pervasive Regulation through Alternative Promoters
Demircioğlu, D., Cukuroglu, E., Kindermans, M., Nandi, T., Calabrese, C., Fonseca, N. A., Kahles, A., Lehmann, K.-V., Stegle, O., Brazma, A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.08.018 · Cited by 250
Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M., & Efferth, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.06.018 · Cited by 248
Chang, J., Tan, W., Ling, Z., Xi, R., Shao, M., Chen, M., Luo, Y., Zhao, Y., Liu, Y., Huang, X., et al. (2017) · Nature Communications · doi:10.1038/ncomms15290 · Cited by 248
Decker, W. K., da Silva, R. F., Sanabria, M. H., Angelo, L. S., Guimarães, F., Burt, B. M., Kheradmand, F., & Paust, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00829 · Cited by 246
Genomic and immune profiling of pre-invasive lung adenocarcinoma
Chen, H., Carrot-Zhang, J., Zhao, Y., Hu, H., Freeman, S. S., Yu, S., Ha, G., Taylor, A. M., Berger, A. C., Westlake, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13460-3 · Cited by 243
Survival Outcomes in Cancer Patients Predicted by a Partial EMT Gene Expression Scoring Metric
George, J. T., Jolly, M. K., Xu, S., Somarelli, J. A., & Levine, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3521 · Cited by 244
Herbst, R. S., Gandara, D. R., Hirsch, F. R., Redman, M. W., LeBlanc, M., Mack, P. C., Schwartz, L. H., Vokes, E., Ramalingam, S. S., Bradley, J. D., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3473 · Cited by 244
“Detailed genomic analysis has identified potential therapeutic targets in over 60% of lung SCCA patients; each of these targets exists in a relatively rare subset of patients (2).”
Ferone, G., Song, J.-Y., Sutherland, K. D., Bhaskaran, R., Monkhorst, K., Lambooij, J.-P., Proost, N., Gargiulo, G., & Berns, A. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.001 · Cited by 244
Singhal, S., Stadanlick, J., Annunziata, M. J., Rao, A. S., Bhojnagarwala, P. S., O’Brien, S., Moon, E. K., Cantu, E., Danet-Desnoyers, G., Ra, H.-J., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat1500 · Cited by 244
KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer
Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.005 · Cited by 243
“Notably, histonemethylationmodifiers and other epigenetic modifiers are often mutated in lung tumors, including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), which comprise 40%–50% and 25%– 30% of lung cancer, respectively (Campbell et al., 2016; Cancer Genome Atlas Research Network, 2012, 2014;…”
BackgroundInfluentialTherapeutic Targeting of Cancers with Loss of PTEN Function
Dillon, L., & Miller, T. (2014) · Current Drug Targets · doi:10.2174/1389450114666140106100909 · Cited by 241
Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer
Jiang, L., Huang, J., Higgs, B. W., Hu, Z., Xiao, Z., Yao, X., Conley, S., Zhong, H., Liu, Z., Brohawn, P., et al. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005895 · Cited by 241
Bromodomains: Structure, function and pharmacology of inhibition
Ferri, E., Petosa, C., & McKenna, C. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.12.005 · Cited by 229
Hourihan, J. M., Kenna, J. G., & Hayes, J. D. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4944 · Cited by 233
Choi, W., Ochoa, A., McConkey, D. J., Aine, M., Höglund, M., Kim, W. Y., Real, F. X., Kiltie, A. E., Milsom, I., Dyrskjøt, L., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.010 · Cited by 234
Rodak, O., Peris-Díaz, M. D., Olbromski, M., Podhorska-Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 233
“Thus, accurate histological diagnosis has become crucial, since each histological type of NSCLC is associated with a characteristic range of gene mutations [12,48,49].”
BackgroundLopez-Chavez, A., Thomas, A., Rajan, A., Raffeld, M., Morrow, B., Kelly, R., Carter, C. A., Guha, U., Killian, K., Lau, C. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.2007 · Cited by 233
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.